gsk6097608 + dostarlimab + belrestotug

This drug is an investigational **combination therapy** of three agents: **GSK6097608**, **dostarlimab**, and **belrestotug** (also known as GSK4428859A, EOS884448). The combination is being studied for the treatment of advanced solid tumors and non-small cell lung cancer (NSCLC), primarily in early-phase clinical trials. - **GSK6097608** is an investigational anticancer drug administered by intravenous infusion, currently in phase 1 studies for advanced solid tumors. The mechanism of action is not publicly specified in detail but likely involves immunomodulation or direct antitumor activity[1][3][5][7]. - **Dostarlimab** is a monoclonal antibody that inhibits **programmed cell death protein 1 (PD-1) receptor**, thereby enhancing the immune system’s anti-tumor response. It is FDA-approved for endometrial and certain solid tumors[8]. - **Belrestotug** is a monoclonal antibody targeting **TIGIT (T cell immunoreceptor with Ig and ITIM domains)**, another immune checkpoint, aiming to potentiate anti-tumor immunity, and is under investigation for solid tumors, particularly NSCLC[2][3][6]. The combination is given intravenously to patients with advanced or metastatic solid tumors, with a special focus on NSCLC (especially PD-L1-high subtypes). The intended mechanism is to synergistically enhance immune checkpoint blockade by inhibiting two key inhibitory pathways in T cells (PD-1 and TIGIT), possibly combined with target effects from GSK6097608[2][3][6]. Early-phase clinical data for the triple combination exist, but belrestotug-based development programs have been discontinued by GSK in NSCLC after lack of PFS benefit in phase 2[6].

Other names

GSK6097608 + dostarlimab + belrestotugdostarlimab-gxlyEOS884448EOS-884448EOS 884448GSK4428859AGSK-4428859AGSK 4428859A